Replies to post #44402 on NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Really? So far NWBO is up to $767,670 per patient. How? $261mm spent on R&D from 2007-today, 300 patients enrolled in P3 and 40 in Direct P1. $261mm /340=$767,670.

The average cost per patient of a phase 3 is around $50k (includes manufacturing, CRO, trial site fees, etc).

NWBO is spending just a little more than average.